Rubicon Genomics introduces
PicoPlex single cell whole genome amplification kit
2 July 2009
Rubicon Genomics, Inc., a developer of pre-amplification products
that enable optimal performance of the most advanced genetic analysis
tools, has announced the release of its PicoPlex Single Cell Whole
Genome Amplification (WGA) kit — a more rapid, accurate and reproducible
method for amplifying single genomes than current technologies.
This product targets the pre-implantation genetic diagnostics (PGD),
cancer research and stem cell research markets, which require rapid,
reproducible amplification to profile patient genotypes, karyotypes and
mutations. PicoPlex enables reference labs to begin qPCR, microarray or
sequencing analysis less than three hours after collecting patient
cells.
“With the PicoPlex Single Cell WGA kit, researchers can now obtain
the same amount of genomic information from one cell as they do from
10,000 cells,” said James Koziarz, acting president and CEO of Rubicon
Genomics.
“We use the PicoPlex Single Cell WGA technology because it
reproducibly amplifies a large percentage of the genome every time,”
said Mark Hughes, CEO of Genesis Genetics Institute, a pioneer in
pre-implantation genomics diagnostics that has evaluated dozens of
single cell WGA technologies over the past 16 years.
“And the few genomic alleles that are under-represented in the
one-cell WGA are predictable, making the data sets easy to anticipate
and accommodate. We like the predictability of this product when
examining many alleles from single haploid and diploid cells.”
Researchers can use the PicoPlex Single Cell WGA kits to reliably
extract more genetic information from single cells with minimal
background. Specifically, the kit reproducibly amplifies total DNA one
million-fold from single cells to produce five micrograms of amplified
DNA in less than three hours.
Current single-cell WGA kits using molecular displacement
amplification (MDA) technology do not offer reproducible amplification
of whole genomes, causing sporadic allele and locus dropouts, which
seriously compromise results in PGD. Hence, microarray and qPCR genetic
analysis of single cells using MDA-amplified DNA is noisy and produces
unreliable data.
Fluorescence In Situ Hybridization (FISH) technology has historically
been used to examine the chromosomes in PGD, but many laboratories are
moving away from this subjective assessment of one cell. Newer
technologies employ qPCR and comparative genomic hybridization (CGH) on
microarrays. These require high fidelity, genome-wide DNA amplification
technology. With PicoPlex Single Cell WGA, researchers can now
confidently employ microarrays and qPCR for more accurate genotyping,
karotyping and copy number variation analysis from single cells.
PicoPlex’s ability to amplify genomic DNA from single cells opens new
avenues for research on embryos, stem cells and cancer cells. For
oncologists, the PicoPlex Single Cell WGA kit may enable more specific
diagnosis or prognosis using a patient’s circulating cancer cells.
Additionally, it enables the study of heterogeneity of cancer cells
creating a better understanding of the broader range of gene expression
in each cell, helping researchers potentially identify more specific
cancer biomarkers.
Bookmark this page